MA23838A1 - Solution aqueuse d'interferon x - Google Patents

Solution aqueuse d'interferon x

Info

Publication number
MA23838A1
MA23838A1 MA24195A MA24195A MA23838A1 MA 23838 A1 MA23838 A1 MA 23838A1 MA 24195 A MA24195 A MA 24195A MA 24195 A MA24195 A MA 24195A MA 23838 A1 MA23838 A1 MA 23838A1
Authority
MA
Morocco
Prior art keywords
interferon
aqueous solution
aqueous
solution
Prior art date
Application number
MA24195A
Other languages
English (en)
Inventor
Delterzo Sabino
Gross Gunter
Kandakuri Kumar Saran
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA23838A1 publication Critical patent/MA23838A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
MA24195A 1995-04-06 1996-04-01 Solution aqueuse d'interferon x MA23838A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95105166 1995-04-06

Publications (1)

Publication Number Publication Date
MA23838A1 true MA23838A1 (fr) 1996-12-31

Family

ID=8219166

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24195A MA23838A1 (fr) 1995-04-06 1996-04-01 Solution aqueuse d'interferon x

Country Status (31)

Country Link
US (1) US5762923A (fr)
EP (1) EP0736303B1 (fr)
JP (1) JP2758154B2 (fr)
KR (1) KR100212346B1 (fr)
CN (1) CN1066065C (fr)
AR (1) AR002932A1 (fr)
AT (1) ATE183650T1 (fr)
AU (1) AU685356B2 (fr)
BR (1) BR9601276A (fr)
CA (1) CA2172664C (fr)
CO (1) CO4750807A1 (fr)
CY (1) CY2194B1 (fr)
CZ (1) CZ287626B6 (fr)
DE (1) DE69603894T2 (fr)
DK (1) DK0736303T3 (fr)
ES (1) ES2136910T3 (fr)
GR (1) GR3031775T3 (fr)
HU (1) HU227643B1 (fr)
IL (1) IL117752A (fr)
MA (1) MA23838A1 (fr)
MY (1) MY113594A (fr)
NO (1) NO316801B1 (fr)
NZ (1) NZ286300A (fr)
PE (1) PE38897A1 (fr)
PL (1) PL183873B1 (fr)
RU (1) RU2113845C1 (fr)
SA (1) SA96160728B1 (fr)
SG (1) SG52806A1 (fr)
TR (1) TR199600287A2 (fr)
TW (1) TW426523B (fr)
ZA (1) ZA962553B (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6402718B1 (en) 1992-08-17 2002-06-11 Medrad, Inc. Front-loading medical injector and syringe for use therewith
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
DE69729880T3 (de) * 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
CA2324467C (fr) * 1998-03-26 2002-11-05 Schering Corporation Formulations servant a proteger des conjugues de peg et d'alpha-interferon
ES2288018T3 (es) * 1998-04-03 2007-12-16 Novartis Vaccines And Diagnostics, Inc. Formulaciones inyectables de igf que contienen succinato como tampon.
DE69901321T2 (de) 1998-05-15 2002-12-12 Schering Corp., Kenilworth Kombinationstherapie enthaltend Ribavirin und Interferon alpha bei Patienten mit chronischer Hepatitis C Infektion, die nicht antiviral vorbehandelt sind
JP3839667B2 (ja) * 1998-06-08 2006-11-01 エフ．ホフマン−ラ ロシュ アーゲー 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
CA2335340C (fr) * 1998-07-23 2013-03-05 Eli Lilly And Company Formulations de fsh et de variants de fsh, produits et procedes
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
ATE298251T1 (de) 1998-08-06 2005-07-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
JP2002532556A (ja) * 1998-12-22 2002-10-02 シェリング・コーポレーション Ｃ型肝炎ウイルス感染のインターロイキン−１０での処置
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
EP1535622B1 (fr) 1999-04-08 2008-12-31 Schering Corporation Thérapie du mélanome
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6923966B2 (en) * 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
KR100399156B1 (ko) * 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
PT1343518E (pt) 2000-11-07 2009-08-03 Novartis Vaccines & Diagnostic Composições de interferão estabilizadas
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
JP2002265383A (ja) * 2001-03-14 2002-09-18 Mitsubishi Pharma Corp インターフェロンα注射用液状製剤
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2002083165A1 (fr) * 2001-04-10 2002-10-24 Sumitomo Pharmaceuticals Co., Ltd. Preparations stables destinees a etre injectees
LT4947B (lt) 2001-09-26 2002-08-26 Biotechnologijos Institutas Interferono alfa farmacinė kompozicija
WO2005003296A2 (fr) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Proteines hybrides d'albumine
CA2841097A1 (fr) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumine et proteines hybrides g-csf
JP5000848B2 (ja) 2002-05-21 2012-08-15 第一三共株式会社 グレリン含有医薬組成物
RU2238758C2 (ru) * 2002-07-24 2004-10-27 Закрытое акционерное общество "Вектор-Медика" Водный раствор интерферона-альфа-два человека для инъекций
WO2004087213A1 (fr) 2003-04-02 2004-10-14 Ares Trading S.A. Formulations pharmaceutiques fsh et lh
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
WO2004112826A1 (fr) 2003-06-20 2004-12-29 Ares Trading Sa Formulations lyophilisees a base de fsh/lh
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
AR045258A1 (es) * 2003-08-21 2005-10-19 Altana Pharma Ag Un producto farmaceutico para inyeccion
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US7879320B2 (en) 2004-05-17 2011-02-01 Ares Trading S.A. Hydrogel interferon formulations
US7731948B2 (en) 2004-06-01 2010-06-08 Ares Trading S.A. Stabilized interferon liquid formulations
EA012281B1 (ru) * 2004-06-01 2009-08-28 Арес Трейдинг С.А. Способ стабилизации белков
RU2255729C1 (ru) * 2004-07-26 2005-07-10 Общество С Ограниченной Ответственностью "Фармапарк" Препарат интерферона альфа в форме стабильного водного раствора для инъекций
EP1796647B1 (fr) 2004-08-12 2010-08-11 Schering Corporation Preparation stable d'interferon pegyle
BRPI0514408B8 (pt) * 2004-08-24 2021-05-25 Asubio Pharma Co Ltd preparação liquida de peptídeo fisiologicamente ativo
RU2270692C1 (ru) * 2004-11-04 2006-02-27 Валентина Васильевна Малиновская Пролонгированный раствор интерферона
KR20080009111A (ko) 2005-04-11 2008-01-24 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
CA2618068C (fr) 2005-08-05 2016-02-16 Amgen Inc. Formulations pharmaceutiques de proteine aqueuse stable ou d'anticorps et leur preparation
CU23432B6 (es) 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
WO2008026044A2 (fr) * 2006-08-31 2008-03-06 Wockhardt Research Centre Compositions pharmaceutiques de bupropion
WO2008088823A2 (fr) 2007-01-16 2008-07-24 Abbott Laboratories Procédés de traitement d'un psoriasis
WO2008145323A1 (fr) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Formulation pharmaceutique comprenant des interférons
KR101483814B1 (ko) * 2007-09-04 2015-01-16 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
CN101636414B (zh) * 2007-09-04 2012-02-15 厦门伯赛基因转录技术有限公司 聚乙二醇修饰的干扰素α2b及其制备方法和应用
RU2010120674A (ru) * 2007-10-22 2011-11-27 Шеринг Корпорейшн (US) Полностью человеческие анти-vegf-антитела и способы их применения
RS52417B (sr) 2007-12-20 2013-02-28 Merck Serono S.A. Formulacije peg-interferona-beta
EP2305309A2 (fr) 2008-06-13 2011-04-06 Proyecto de Biomedicina Cima, S.L. Conjugués pour l'administration de composés biologiquement actifs
JP2012502906A (ja) * 2008-09-17 2012-02-02 ネクター セラピューティックス オリゴマー−プロテアーゼ阻害剤コンジュゲート
JP2012531596A (ja) 2009-06-25 2012-12-10 サヴィエント・ファーマシューティカルズ・インコーポレイテッド Ｐｅｇ化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
RU2447083C1 (ru) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CN102526758B (zh) * 2012-02-23 2013-02-13 北京三元基因工程有限公司 一种聚乙二醇化干扰素稳定的水溶液
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
WO2016046101A1 (fr) * 2014-09-23 2016-03-31 F. Hoffmann-La Roche Ag Formulations stables, exemptes d'alcool benzylique, d'une solution aqueuse contenant de l'interféron de type alpha
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
WO2020160325A1 (fr) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Réduction de l'immunogénicité de la pegloticase
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
RU2768656C1 (ru) * 2021-09-10 2022-03-24 Илья Александрович Марков Противовирусное средство в жидкой форме и способ его приготовления
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物
RU2007184C1 (ru) * 1985-11-25 1994-02-15 Научно-исследовательский институт эпидемиологии и микробиологии им.Н.Ф.Гамалеи РАМН Способ лечения сальмонеллезной инфекции
EP0284249A1 (fr) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Composition lyophilisée de lymphokine
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JPH0651642B2 (ja) * 1988-11-14 1994-07-06 大塚製薬株式会社 インターフェロン経鼻投与用製剤
EP0396777A4 (en) * 1988-11-14 1991-03-13 Otsuka Pharmaceutical Co., Ltd. Interferon preparation for nasal administration
CA2033714A1 (fr) * 1990-01-25 1991-07-26 Alberto Ferro Preparations pharmaceutiques
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid compositions of gamma interferon

Also Published As

Publication number Publication date
MY113594A (en) 2002-04-30
US5762923A (en) 1998-06-09
CY2194B1 (en) 2002-11-08
EP0736303A3 (fr) 1997-02-26
AU5044696A (en) 1996-10-17
CN1141808A (zh) 1997-02-05
JP2758154B2 (ja) 1998-05-28
CO4750807A1 (es) 1999-03-31
SA96160728B1 (ar) 2005-05-04
PE38897A1 (es) 1997-10-04
NO961322L (no) 1996-10-07
CZ99496A3 (en) 1996-10-16
NO961322D0 (no) 1996-04-01
BR9601276A (pt) 1998-01-13
HU227643B1 (en) 2011-10-28
IL117752A (en) 2000-11-21
AU685356B2 (en) 1998-01-15
GR3031775T3 (en) 2000-02-29
CA2172664C (fr) 2000-10-03
EP0736303B1 (fr) 1999-08-25
PL313655A1 (en) 1996-10-14
AR002932A1 (es) 1998-05-27
HU9600857D0 (en) 1996-05-28
RU2113845C1 (ru) 1998-06-27
CA2172664A1 (fr) 1996-10-07
NO316801B1 (no) 2004-05-18
PL183873B1 (pl) 2002-07-31
TW426523B (en) 2001-03-21
CZ287626B6 (en) 2001-01-17
JPH08283176A (ja) 1996-10-29
ATE183650T1 (de) 1999-09-15
HUP9600857A3 (en) 1998-01-28
SG52806A1 (en) 1998-09-28
DE69603894D1 (de) 1999-09-30
ES2136910T3 (es) 1999-12-01
KR960037063A (ko) 1996-11-19
EP0736303A2 (fr) 1996-10-09
TR199600287A2 (tr) 1997-03-21
NZ286300A (en) 1997-05-26
ZA962553B (en) 1996-10-07
DE69603894T2 (de) 2000-04-20
KR100212346B1 (ko) 1999-08-02
IL117752A0 (en) 1996-08-04
CN1066065C (zh) 2001-05-23
DK0736303T3 (da) 2000-01-10
HUP9600857A2 (en) 1997-08-28
HK1012232A1 (en) 1999-07-30

Similar Documents

Publication Publication Date Title
EP0736303A3 (fr) Solution d'interféron
FI20055562L (fi) Alfa-interferonin stabiilit vesiliuosformulaatit
FI955305L (fi) Tekijä VIII:n vähähappinen vesiliuos
FI963902L (fi) Kissojen kasvoferomonien ominaisuudet
BR9510256A (pt) Derivados de ácido 3-aril-tetrônico
EP0765166A4 (fr) Conjugues radiomarques d'annexine-galactose
EP0826033A4 (fr) Gene de l'ataxie-telangiectasie
TR199701051A3 (tr) 2' -Fluoro-5-metil- -l-arabino-furanosilüridin hazirlanma prosesi
DE59609043D1 (de) Feste Lösungen von 1,4-Diketopyrrolopyrrolen
FI960425L (fi) Fenyylisykloheksyylikarboksyylihappoamidien käyttö
MA23133A1 (fr) Derives d'acide d'acyloxyhexanoique .
DE59504988D1 (de) Niedrigviskose wässrige konzentrate von betaintensiden
EP1004309A4 (fr) Preparations aqueuses contenant de l'israpafant
EP1136472A4 (fr) Aryl- et heteroarylamides d'acides carboalcoxysulfaniliques
FI933436A7 (fi) Vaexelspaks frilaegeslaosning
FR2735986B3 (fr) Prolongateur d'haltere
FR2769017B1 (fr) Concentres aqueux d'alkyl-betaine basse viscosite
EP0741671A4 (fr) Biodegradation d'acide methane-sulfonique
ITRM940334A0 (it) Reiezione di "clutter" utilizzando connettivita
ITTO950129V0 (it) "cornice predisposta per l'illuminazione di ambienti, applicata a qua-dri e/o a specchiere"
FR2647300B1 (fr) Variete d'hypoestes sanguinolenta " 1189 "
ES1020655Y (es) "prenda de aspecto cambiante"
KR970029596U (ko) 윈도우의 시야확보장치
ITMI930218A1 (it) Derivato peptidico della rimantadina di attivita' immunomodulante
ITRM950072V0 (it) Brevetto "mascia" (maglia-sciarpa)